University of Szeged Joins European COST Action on Cell‑Based Therapies in Hungary

University of Szeged Joins European COST Action on Cell‑Based Therapies in Hungary

Overview of the BTCs4ATMP Initiative

The European COST Action CA24114, titled BTCs4ATMP (Blood, Tissue and Cells for Advanced Therapy Medicinal Products), was launched in October 2025. Its purpose is to create a coordinated network that links blood, tissue, and cell banks with researchers, clinicians, industry partners, and regulatory authorities across the continent. The University of Szeged (SZTE) has become a consortium member, positioning Hungary at the forefront of this collaborative effort.

What is a COST Action?

Cost (European Cooperation in Science and Technology) Actions are research and innovation projects funded by the European Union that bring together experts from multiple countries. They are designed to strengthen scientific cooperation, share best practices, and accelerate the translation of research into real‑world solutions. Unlike traditional grant programmes, COST Actions focus on networking and knowledge exchange rather than direct funding of research projects.

Role of the University of Szeged

As a leading Hungarian institution, SZTE contributes through its Personalized Medicine Research Infrastructure, one of Hungary’s top 50 research infrastructures. The university’s expertise in cell biology, GMP‑compliant manufacturing, and biobank management makes it an ideal partner for the BTCs4ATMP network. SZTE’s participation also signals a commitment to ensuring that advanced therapy medicinal products (ATMPs) meet the highest quality and safety standards.

Impact on Cell‑Based Therapies Development

Cell‑based therapies, including CAR‑T cell treatments and mesenchymal stem cell (MSC) therapies, represent the next frontier in personalized medicine. However, their development is highly sensitive to variations in cell isolation, handling, and quality control. The BTCs4ATMP initiative addresses these challenges by:

  • Establishing harmonised protocols for the processing of Substances of Human Origin (SoHO).
  • Creating a shared platform for data exchange and best‑practice guidelines.
  • Facilitating joint training programmes to build a skilled workforce across Europe.

From Research to Clinical Practice

Bridging the gap between laboratory discovery and patient care requires more than scientific breakthroughs. It demands robust manufacturing pipelines, regulatory alignment, and ethical oversight. By integrating blood, tissue, and cell banks into a single network, BTCs4ATMP ensures that each step—from donor selection to final product administration—adheres to consistent standards. This reduces duplication of effort, speeds up regulatory approvals, and ultimately brings life‑saving therapies to patients faster.

Quality Assurance and Standardization

One of the core challenges in ATMP development is maintaining product identity, purity, and potency across different production sites. The BTCs4ATMP working groups focus on:

  • Developing validated analytical methods for cell characterization.
  • Defining acceptance criteria for cell viability, sterility, and genetic stability.
  • Implementing traceability systems that link donor information to final therapeutic products.

These efforts help create a common language for quality that regulators and industry can rely on, reducing uncertainty and fostering confidence among stakeholders.

Opportunities for Researchers and Clinicians

Participation in the BTCs4ATMP network offers several tangible benefits for scientists, clinicians, and industry partners:

  • Access to a pan‑European network of expertise—including leading cell banks, GMP facilities, and regulatory specialists.
  • Collaborative research projects—with funding opportunities and shared resources.
  • Opportunities to contribute to the development of European standards for cell‑based therapies.
  • Training programmes that cover the latest techniques in cell isolation, expansion, and quality control.

Collaboration Across Europe

By joining forces, member institutions can pool resources to tackle complex scientific questions that would be difficult to address individually. For example, joint studies on MSC potency assays or CAR‑T cell manufacturing scalability can accelerate the translation of promising therapies into clinical trials.

Training and Workforce Development

One of the key deliverables of the BTCs4ATMP Action is the creation of a comprehensive training curriculum. This curriculum covers:

  • Cell culture best practices.
  • GMP compliance and documentation.
  • Regulatory pathways for ATMPs.
  • Ethical considerations in cell therapy research.

Participants can earn certificates that are recognised across Europe, enhancing their employability and professional credibility.

How the University of Szeged Supports the Initiative

Szeged’s contribution extends beyond mere membership. The university’s infrastructure and expertise are leveraged in several ways:

Personalized Medicine Research Infrastructure

As a top‑tier research infrastructure, SZTE provides:

  • High‑throughput screening facilities for cell‑based assays.
  • Advanced bioinformatics platforms for data analysis.
  • Collaborative spaces that facilitate interdisciplinary projects.

Biobank and GMP Facilities

The university’s biobank, managed under the IKIKK GMP Advanced Core Facility, offers:

  • State‑of‑the‑art cell processing units compliant with GMP standards.
  • Long‑term storage solutions for donor cells and tissues.
  • Quality control laboratories that perform sterility, endotoxin, and potency testing.

These facilities enable the university to serve as a reference centre for the BTCs4ATMP network, ensuring that all participating sites can meet the same high standards.

Getting Involved

Researchers, clinicians, and industry partners interested in contributing to the BTCs4ATMP Action can apply through the network’s official portal. The application process typically involves:

  • Submitting a brief proposal outlining the intended contribution.
  • Providing evidence of existing infrastructure or expertise.
  • Demonstrating alignment with the Action’s objectives.

For more detailed information, visit the official COST Action page.

Contact Information

To discuss potential collaboration or to clarify application details, contact the University of Szeged’s International Relations Office:

  • Phone: (+36-62) 544-000
  • Email: [email protected]
  • Address: 13 Dugonics square, Szeged H-6720, Hungary

Conclusion

The launch of the BTCs4ATMP European COST Action marks a significant step toward standardising and accelerating the development of cell‑based therapies across the continent. With the University of Szeged’s active participation, Hungary is positioned to influence the future of advanced therapy medicinal products, ensuring that patients receive safe, effective, and accessible treatments.

Researchers and clinicians who wish to contribute to this transformative effort are encouraged to explore the available opportunities and apply through the official channels. By joining this network, you can help shape the next generation of personalized medicine.

Submit your application today to become part of this pioneering initiative.

For further guidance, schedule a free consultation with our international office.

Have questions? Write to us!

Explore our related articles for further reading on cell‑based therapies and European research collaborations.